RLMD – relmada therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) was downgraded by analysts at Mizuho from a "strong-buy" rating to a "hold" rating.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "market perform" rating re-affirmed by analysts at Leerink Partners. They now have a $1.00 price target on the stock, down previously from $10.00.
Relmada Therapeutics, Inc. (NASDAQ: RLMD) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $1.00 price target on the stock, down previously from $23.00.
Form 8-K RELMADA THERAPEUTICS, For: Dec 09
Form SC 13G/A RELMADA THERAPEUTICS, Filed by: Deep Track Capital, LP
Form 10-Q RELMADA THERAPEUTICS, For: Sep 30
Form 4 RELMADA THERAPEUTICS, For: Oct 22 Filed by: CASAMENTO CHARLES J
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.